{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-26-347907","form_type":"8-K","ticker":"INKT","cik":"0001840229","company_name":"MiNK Therapeutics, Inc.","filed_at":"2026-08-13T11:40:44+00:00","discovered_at":"2026-08-13T11:45:13.375986+00:00","generated_at":"2026-08-13T11:45:20.212725+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"MiNK Q2 2026 net loss $3.1M, cash $8.8M; Phase 2 ALI data positive","bullets":["Net loss $3.1M ($0.62/share) vs $4.2M ($1.06) in Q2 2025; six-month loss $5.9M vs $7.0M.","Cash $8.8M at June 30, 2026, down from $9.5M at March 31 and $13.4M at Dec 31, 2025.","Randomized Phase 2 (C-1300-02) in acute lung injury: first patients alive at Day 28, improved oxygenation, infection control, ventilator/vasopressor liberation; no major SAEs.","Established first paid international named-patient access program in Brazil via Orphan Drug Consulting for agenT-797.","Data presented at MHSRS; U.S. expansion underway, more data expected early 2027."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-26-347907","json":"https://secwatch.observer/filing/0001193125-26-347907.json","markdown":"https://secwatch.observer/filing/0001193125-26-347907.md","text":"https://secwatch.observer/filing/0001193125-26-347907.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1840229/000119312526347907/0001193125-26-347907-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1840229/000119312526347907/inkt-20260813.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-08-13T11:45:20.212725+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}